Ironwood Pharmaceuticals (IRWD) Net Income towards Common Stockholders (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Net Income towards Common Stockholders across 17 years of filings, most recently posting $51.3 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 117.34% year-over-year to $51.3 million; the TTM figure through Jun 2026 stood at $221.0 million (up 135.06% YoY), while the FY2025 annual figure was $115.1 million, up 12.04% from the prior year.
• Net Income towards Common Stockholders came in at $51.3 million for Q2 2026 at Ironwood Pharmaceuticals, up from $40.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $104.2 million in Q4 2024 to a low of -$1.1 billion in Q2 2023.
• Average Net Income towards Common Stockholders over 5 years is -$27.3 million, with a median of $39.4 million recorded in 2022.
• Year-over-year, Net Income towards Common Stockholders slumped 3038.3% in 2023 and soared 2844.07% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at $48.9 million in 2022, then gained by 11.17% to $54.3 million in 2023, then soared by 91.76% to $104.2 million in 2024, then retreated by 14.68% to $88.9 million in 2025, then tumbled by 42.29% to $51.3 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $51.3 million in Q2 2026, $40.8 million in Q1 2026, and $88.9 million in Q4 2025.